Showing results (111-120 of 187) with videos related to
Sort By:
Pageof 19
Clinical and Experimental Rheumatology|December 7, 2021
The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with ageChristof Specker, Martin Aringer, Gerd-Rüdiger Burmester, et al.Arthritis and Rheumatism|October 2, 2007
Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health statusTanja A Stamm, Bettina Bauernfeind, Michaela Coenen, et al.Arthritis Care & Research|May 26, 2017
Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic DataNicolai Leuchten, Annika Hoyer, Ralph Brinks, et al.Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.Arthritis and Rheumatism|May 1, 2009
Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cellsThomas Karonitsch, Eva Feierl, Carl Walter Steiner, et al.Rheumatology (Oxford, England)|June 9, 2023
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung diseaseYannick Allanore, Dinesh Khanna, Vanessa Smith, et al.RMD Open|August 19, 2025
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension studyJoan T Merrill, Amit Saxena, Martin Aringer, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Characterization and analysis of the proximal Janus kinase 3 promoterMartin Aringer, Sigrun R Hofmann, David M Frucht, et al.Zeitschrift Fur Rheumatologie|May 16, 2019
[Survey of rheumatologists in Saxony, Saxony-Anhalt and Thuringia regarding the occupational situation and activities in further education: no way out of the undersupply of rheumatological care]Gernot Keyßer, Christoph G O Baerwald, Maren Sieburg, et al.Arthritis & Rheumatology (Hoboken, N.J.)|November 3, 2020
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled TrialToby M Maher, Maureen D Mayes, Michael Kreuter, et al.Pageof 19